: Toxoplasmosis is a critical health issue for immune-deficient individuals and the offspring of newly infected mothers. It is caused by a unicellular intracellular parasite called Toxoplasma gondii that is found worldwide. Although efficient drugs are commonly used to treat toxoplasmosis, serious adverse events are common. Therefore, new compounds with potent anti-T. gondii activity are needed to provide better suited treatments. We have tested compounds designed to target specifically histone deacetylase enzymes. Among the 55 compounds tested, we identified three compounds showing a concentration of drug required for 50% inhibition (IC50) in the low 100 nM range with a selectivity index of more than 100. These compounds are not only active at inhibiting the growth of the parasite in vitro but also at preventing some of the consequences of the acute disease in vivo. Two of these hydroxamate based compound also induce a hyper-acetylation of the parasite histones while the parasitic acetylated tubulin level remains unchanged. These findings suggest that the enzymes regulating histone acetylation are potent therapeutic targets for the treatment of acute toxoplasmosis.

Hydroxamate-based compounds are potent inhibitors of Toxoplasma gondii HDAC biological activity / Boissavy, Tom; Rotili, Dante; Mouveaux, Thomas; Roger, Emmanuel; Aliouat, El Moukthar; Pierrot, Christine; Valente, Sergio; Mai, Antonello; Gissot, Mathieu. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 0066-4804. - 67:11(2023), p. e0066123. [10.1128/aac.00661-23]

Hydroxamate-based compounds are potent inhibitors of Toxoplasma gondii HDAC biological activity

Rotili, Dante;Valente, Sergio;Mai, Antonello;
2023

Abstract

: Toxoplasmosis is a critical health issue for immune-deficient individuals and the offspring of newly infected mothers. It is caused by a unicellular intracellular parasite called Toxoplasma gondii that is found worldwide. Although efficient drugs are commonly used to treat toxoplasmosis, serious adverse events are common. Therefore, new compounds with potent anti-T. gondii activity are needed to provide better suited treatments. We have tested compounds designed to target specifically histone deacetylase enzymes. Among the 55 compounds tested, we identified three compounds showing a concentration of drug required for 50% inhibition (IC50) in the low 100 nM range with a selectivity index of more than 100. These compounds are not only active at inhibiting the growth of the parasite in vitro but also at preventing some of the consequences of the acute disease in vivo. Two of these hydroxamate based compound also induce a hyper-acetylation of the parasite histones while the parasitic acetylated tubulin level remains unchanged. These findings suggest that the enzymes regulating histone acetylation are potent therapeutic targets for the treatment of acute toxoplasmosis.
2023
HDAC; apicomplexa; histone deacetylase inhibitors; toxoplasma; toxoplasmosis
01 Pubblicazione su rivista::01a Articolo in rivista
Hydroxamate-based compounds are potent inhibitors of Toxoplasma gondii HDAC biological activity / Boissavy, Tom; Rotili, Dante; Mouveaux, Thomas; Roger, Emmanuel; Aliouat, El Moukthar; Pierrot, Christine; Valente, Sergio; Mai, Antonello; Gissot, Mathieu. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 0066-4804. - 67:11(2023), p. e0066123. [10.1128/aac.00661-23]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1694442
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 1
social impact